NCT04958122RecruitingPhase 3
Cefixime Clinical Trial
Clinical Trial Comparing the Effectiveness of Cefixime Versus Penicillin G for Treatment of Early Syphilis
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- First submitted
- 29 Jun 2021
- Start date
- 20 Jun 2021
- Primary completion date
- 1 Jan 2027
- Lead sponsor
- University of Southern California
- Diseases
- HIV
- NCT number
- NCT04958122
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 400
- From 20 Jun 2021 to the primary completion date, 1 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent (within the past 7 days) or concomitant antimicrobial therapy with activity against syphilis, namely azithromycin, doxycycline, ceftriaxone, or other beta-lactam antibiotics (e.g. amoxicillin)
Other illness
- Individuals with HIV infection who report HIV treatment interruption for more than 4 weeks since their most recent viral load or CD4 test
- Self-reported allergy to cephalosporins or penicillin
Other
- Pregnancy or a positive pregnancy test on the day of enrollment
- Patients showing signs and symptoms of neurosyphilis
- Serofast RPR titer, defined as persistently positive RPR titer without more than 4-fold (2-titer level) change for 12 months or greater
- Unwilling or unable to attend follow-up visits
Who the study is looking for
- Diagnosed cases of primary, secondary, or early latent syphilis with RPR titer ≥1:8 within 3 weeks prior to enrollment
- 18 years of age or older
- Able to provide informed consent
- Individuals with HIV infection must be on treatment for HIV infection and virologically suppressed (viral load \<200 copies/mL) or have a CD4 count ≥ 350 cells/mm3 according to most recent labs before study enrollment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Southern California Coordinator of this site? Confirm its status | Los Angeles | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.